John Oyler Biography and Net Worth

CEO of Beigene

John V. Oyler co-founded BeiGene in 2010. He has served as CEO and has led the Board of Directors from the company’s start.

Mr. Oyler previously served as President and CEO of BioDuro, LLC, a drug discovery services company, from 2005 its acquisition by PPD in 2009. From 2002 to 2004, Mr. Oyler served as CEO of Galenea Corp., a biopharmaceutical company discovering novel therapies for central nervous system diseases. From 1998 to 2002, Mr. Oyler was the President of Telephia, Inc., an information company he founded and ultimately was acquired by The Nielsen Company. From 1997 to 1998, Mr. Oyler was Co-Chief Executive Officer of Genta Incorporated (NASDAQ: GNTA), an oncology-focused biopharmaceutical company. He began his career as a management consultant at McKinsey & Company.

Mr. Oyler served on the Board of Directors of the Biotechnology Innovation Organization (BIO) from 2019-2024. He also serves on the Stanford Graduate School of Business Advisory Council. Mr. Oyler received his B.S. in mechanical engineering from the Massachusetts Institute of Technology and an MBA from Stanford University. A native of Pittsburgh, he is an avid fan of the city’s Steelers football team and Penguins hockey team, and enjoys skiing and spending time with his family.

What is John Oyler's net worth?: The estimated net worth of John Oyler is at least $2.78 million as of April 10th, 2024. Oyler owns 12,084 shares of Beigene stock worth more than $2,782,704 as of April 21st. This net worth evaluation does not reflect any other assets that Oyler may own. Learn More about John Oyler's net worth.
How do I contact John Oyler?: The corporate mailing address for Oyler and other Beigene executives is C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN, E9, KY1-1108. Beigene can also be reached via phone at 13459494123 and via email at ir@beigene.com. Learn More on John Oyler's contact information.
Has John Oyler been buying or selling shares of Beigene?: John Oyler has not been actively trading shares of Beigene during the last quarter. Most recently, John Oyler sold 58,590 shares of the business's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $249.13, for a transaction totalling $14,596,526.70. Learn More on John Oyler's trading history.
Who are Beigene's active insiders?: Beigene's insider roster includes Chan Lee (SVP), John Oyler (CEO), Lai Wang (Global Head of R&D), Lai Wang (Insider), Xiaodong Wang (Insider), and Xiaobin Wu (COO). Learn More on Beigene's active insiders.
Are insiders buying or selling shares of Beigene?: In the last twelve months, insiders at the sold shares 12 times. They sold a total of 1,146,048 shares worth more than $295,198,300.30. The most recent insider tranaction occured on April, 14th when insider Xiaodong Wang sold 41,760 shares worth more than $10,133,481.60. Insiders at Beigene own 7.4% of the company. Learn More about insider trades at Beigene.
Information on this page was last updated on 4/14/2025.

John Oyler Insider Trading History at Beigene

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/7/2025	Sell	58,590	$249.13	$14,596,526.70
3/3/2025	Sell	101,000	$244.30	$24,674,300.00

John Oyler Buying and Selling Activity at Beigene

Beigene Company Overview

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Today's Range

Now: $230.28

$229.47

$232.51

50 Day Range

MA: $246.17

$206.32

$278.38

2 Week Range

Now: $230.28

$129.96

$287.88

Volume

35,527 shs

Average Volume

485,715 shs

Market Capitalization

$22.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49